Agilent Technologies Inc vs Nvidia Corp — how do they compare? Agilent Technologies Inc trades at $173.35 (market cap $49.02B), while Nvidia Corp trades at $211.6 (market cap $5.12T). The key difference: Nvidia Corp is far larger — about 104.4× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays the higher dividend (0.59%). Which is the better fit depends on your goals — on Pluang, investors hold Agilent Technologies Inc for 38 Days and Nvidia Corp for 116 Days on average.
| A | NVDA | |
|---|---|---|
Market Cap | $49.02B | $5.12T |
Volume | 2,654,424 | 124,963,035 |
Sector | Health | Technology |
52-Week High | $177.76 | $239.27 |
52-Week Low | $110.24 | $165.17 |
Typical Hold Time | 38 Days | 116 Days |
Enterprise Value | $51.22B | $5.10T |
Dividend Yield | 0.59% | 0.47% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $177.76, up 2.69% today and near its 52-week high of $174.77 (Defense World, 2026-09-30). The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q1 and Q2 2026. Revenue is projected to grow to $7.4B in 2026 (company trends), while profitability remains robust with a net income margin of 19.53%. Recent product launches, including the NovoStation and Gen5 AI module (Business Wire, September 2026), highlight innovation momentum.
Outlook is positive given analyst consensus (80% buy ratings) and institutional accumulation, but risks include high valuation multiples (P/E 34.3) and exposure to economic cycles. The stock offers growth potential from lab automation trends, though investors should monitor execution against earnings expectations.
NVIDIA (NVDA) trades at $212.84, down 4.07% today amid a broader tech sell-off. The stock exhibits strong fundamentals with revenue surging to $130.50 billion in 2025 and net income margin at 63.66%. Recent earnings beats and a consensus analyst price target of $339.17 suggest significant upside potential. Technical indicators show a bearish short-term trend with key support at $210 and resistance at $216.
Outlook remains positive driven by AI leadership and robust financials, but risks include market volatility and competitive pressures. The stock presents a long-term growth opportunity, supported by Wall Street's bullish consensus, though investors should monitor execution risks and macroeconomic factors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →